Compass Minerals International, Inc.
—- Market cap
- —
- Debt
- +$847.70M
- Cash
- −$59.70M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CMP stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs Annual EPS, MRNA P/E.
Implied fair value · at CMP's multiple
Needs Annual EPS is negative, CMP P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Compass Minerals International, Inc. · implied price per share
Bear
-$7.09
Base
-$5.01
Bull
-$2.31
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MOSAIC CO
CMP vs MOS
Intrepid Potash, Inc.
CMP vs IPI
MARTIN MARIETTA MATERIALS INC
CMP vs MLM
Vulcan Materials CO
CMP vs VMC
HECLA MINING CO/DE/
CMP vs HL
PFIZER INC
CMP vs PFE
JOHNSON & JOHNSON
CMP vs JNJ
GILEAD SCIENCES, INC.
CMP vs GILD
AMGEN INC
CMP vs AMGN
NOVAVAX INC
CMP vs NVAX
VERTEX PHARMACEUTICALS INC / MA
CMP vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CMP can sustain revenue growth of 11.3% while maintaining positive operating margins of 2.0%, then CMP may deserve to trade closer to its historical band than to MRNA-style multiples because MRNA's 16.3x P/S is driven by a very different and currently loss-heavy profile.
CMP trades at 1.0x P/S versus MRNA at 16.3x and 1.6x EV/Revenue versus 15.3x, while CMP's current price of $29.96 sits near its historical band of $26.96-$32.96. The headline implied price of $484.35 appears driven by applying MRNA's much richer sales multiple, but that multiple is not directly comparable given MRNA's deeply negative margins and earnings.
Supporting Metrics